Literature DB >> 6314582

T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates.

K Lechner, H Niessner, P Bettelheim, E Deutsch, I Fasching, M Fuhrmann, W Hinterberger, C Korninger, E Neumann, K Liszka.   

Abstract

Various immunological parameters were determined in 46 patients with severe hemophilia A and in 9 patients with severe hemophilia B. All patients were treated over many years with commercial factor VIII or IX concentrates. Patients with severe classic hemophilia had a significantly reduced relative and absolute number of T-helper cells and a significantly increased relative and absolute number of T-suppressor cells. About half of these patients had an inverse T-helper/suppressor cell ratio. Patients with moderate hemophilia A and severe hemophilia B did not show these abnormalities. Hemophiliacs with an inverse ratio had a significantly higher concentration of serum total protein, IgG and IgM. No relationship between the amount of factor VIII concentrate administered, the HLA-type of the patient, the presence or absence of CMV-antibodies, hepatitis markers, thrombocytopenia and abnormal liver function tests to the T-cell abnormalities could be established. Lymphadenopathy was frequently associated with an inverse ratio. Indirect evidence suggests that the alterations of the immune system began in 1979/80.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314582

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Progressive change in lymphocyte distribution and degree of hypergammaglobulinemia with age in children with hemophilia.

Authors:  B T Shannon; J Roach; M Cheek-Luten; C Orosz; F B Ruymann
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

2.  Deficiency of the autologous mixed lymphocyte reaction in patients with classic hemophilia treated with commercial factor VIII concentrate. Correlation with T cell subset distribution, antibodies to lymphadenopathy-associated or human T lymphotropic virus, and analysis of the cellular basis of the deficiency.

Authors:  J S Smolen; P Bettelheim; U Köller; S McDougal; W Graninger; T A Luger; W Knapp; K Lechner
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

3.  HTLV III antibodies and immunological alterations in hemophilia patients.

Authors:  E Seifried; G Pindur; H Stötter; F Porzsolt; H Rasche; V Erfle; R Hehlmann; H Heimpel
Journal:  Klin Wochenschr       Date:  1986-02-03

4.  Unusually high incidence of tuberculosis among boys with haemophilia during an outbreak of the disease in hospital.

Authors:  A C Beddall; F G Hill; R H George; M D Williams; K Al-Rubei
Journal:  J Clin Pathol       Date:  1985-10       Impact factor: 3.411

5.  Lymphocyte subset ratios and factor VIII usage in haemophilia.

Authors:  A C Beddall; K Al-Rubei; M D Williams; F G Hill
Journal:  Arch Dis Child       Date:  1985-06       Impact factor: 3.791

6.  Lymphocytes of haemophilia patients treated with clotting factor concentrates display activation-linked cell-surface antigens.

Authors:  U Köller; O Majdic; K Liszka; H Stockinger; I Pabinger-Fasching; K Lechner; W Knapp
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

7.  Expansion of a minor subpopulation of peripheral blood lymphocytes (T8+/Leu 7+) in patients with haemophilia.

Authors:  H W Ziegler-Heitbrock; W Schramm; D Stachel; H Rumpold; D Kraft; D Wernicke; K von der Helm; J Eberle; F Deinhardt; E P Rieber
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.